Abstract

LIVER BIOPSY OR FIBROSCAN

Goran Topi?*, Biljana Topi?, Renata Tamburi? and Vlado ?aji?

.

Abstract

The liver is the most complex organ in terms of metabolism. Specific diseases primarily affect certain parts of the hepatobiliary system (e.g. acute viral hepatitis is primarily manifested by liver cell damage or hepatocellular damage, primary biliary cirrhosis by impaired bile secretion, and cryptogenic cirrhosis by liver fibrosis and consequent portal hypertension). FibroScan (FS) is a non-invasive, reliable method, which serves to detect liver cirrhosis and exclude significant liver fibrosis and steatosis. Unlike a standard biopsy, there is no pain or risk of bleeding and other complications. The examination was performed using FibroScan mini 430+, the latest generation from 2022. Fast, Agile 3+ Agile 4 calculators were used for the analysis. Fatty liver disease is a major socio-epidemiological problem. Today it is presented as the leading cause of diffuse liver disease. It is associated with cardiovascular risk and metabolic disease. It is also a risk factor for hepatocellular carcinoma, which continues to increase significantly worldwide. Based on our study, we concluded that the use of FibroScan is relatively accessible, with less financial burden, non-invasive for the patient, and significant data on the liver disease itself is obtained, which correctly identifies patients

Keywords: FibroScan, steatosis, liver fibrosis, NASH, NAFLD.